胰高血糖素样肽1(GLP-1)受体激动剂可减轻体重,降低血糖、血压、血脂,改善炎症,这些作用有助于降低心血管事件的发生风险。心血管结局试验(CVOT)已经证实GLP-1受体激动剂降低了T2DM患者主要心血管不良事件的发生率。GLP-1受体激动剂用于射血分数保留的心...
3. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonist. Front Endocrinol, 2024, 15: 1431292. 4. Informa数据库, 检索日期: 2024年11月15日. 5. 药渡数据库, 检索日期: 2024年11月15日. 6. 药明...
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonistsdoi:10.3389/fendo.2024.1431292TYPE 2 diabetesCARDIOVASCULAR diseasesMETABOLIC disordersPANCREATIC secretionsREGULATION of body weightGLUCAGON receptorsGlucose-dependent insulinotropic polypeptide (...
表1:临床研究中的GLP-1类似物(数据来源:汤森路透) 可以预期,随着研究的进一步开展,GLP-1在未来T2DM的治疗中将发挥更大作用,依从性和治疗效果更好的GLP-1产品将改善糖尿病患者的治疗现状。 参考文献: Drucker DJ., et al. Mechanisms of Action and TherapeuticApplication of Glucagon-like Peptide-1. Cell Metab...
[5] Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.[6] Howell E, Baumgartner HM, Zallar LJ, et al. Glucagon-LikePeptide-1 (GLP-1) and 5-Hydroxytryptamine 2c (5-HT(2c)) Receptor Agonists in the ...
[34] Drucker, D.J. 2018. Mechanisms of Action and Therapeutic Application of Glucagonlike Peptide-1. Cell Metab 27:740-756. [35] Fridolf, T., Bottcher, G., Sundler, F., Ahren, B. 1991. GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretio...
可以预期,随着研究的进一步开展,GLP-1在未来T2DM的治疗中将发挥更大作用,依从性和治疗效果更好的GLP-1产品将改善糖尿病患者的治疗现状。 参考文献: 1. Drucker DJ., et al. Mechanisms of Action and TherapeuticApplication of Glucagon-like Peptide-1. Cell Metabolism. 2018; 27: 740-756. ...
[6] Cummings, D.E., Overduin, J., Shannon, M.H., Foster-Schubert, K.E., Conference,A.B.S.C. 2005. Hormonal mechanisms of weight loss and diabetes resolution after bariatricsurgery. Surg Obes Relat Dis 1:358-368. [7] Peterli, R., Wolnerhanssen, B., Peters, T., Devaux, N.,...
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. [6] Howell E, Baumgartner HM, Zallar LJ, et al. Glucagon-LikePeptide-1 (GLP-1) and 5-Hydroxytryptamine 2c (5-HT(2c)) Receptor Agonists in the Ventral Tegmental Area (VTA) ...
[1]Ussher, J. R., & Drucker, D. J. (2023). Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nature reviews. Cardiology, 20(7), 463–474. https://doi.org/10.1038/s41569-023-00849-3 [2]Deanfield, J., Verma, S., Scirica, B. M., ...